Active substance Sofosbuvir + Velpatasvir
US Brand Generic Epclusa
IN Brand Sofosvel | Velpanat | Velasof
Manufacturing by Beacon | Natco | Hetero
Strength 400mg + 100mg
Form release blister 6 tabs | bottle 28 tabs
Estimated shipping time 7 – 18 days (Depending from the Country)
Availability, Prices & Order through request form

DescriptionDosageSide EffectsPhotos

Sofosbuvir-velpatasvir is the first available pangenotypic NS5A-NS5B inhibitor single-pill combination regimen, and is highly efficacious across HCV genotypes 1 to 6. It provides a much-needed interferon-free option for patients with genotype 3 infection that is more economical than sofosbuvir plus daclatasvir, and in patients who have compensated cirrhosis with genotype 3, this single-pill option provides an important ribavirin-free combination that will prove a welcome alternative to what has been available to date. Notably, unlike ledipasvir-sofosbuvir, an abbreviated duration of 8 weeks has not been studied with sofosbuvir-velpatasvir for any of the genotypes, except in conjunction with a third agent (GS-9857, an investigational pangenotypic HCV protease inhibitor). Sofosbuvir-velpatasvir, like ledipasvir-sofosbuvir, will be susceptible to drug interactions with acid-reducing agents particularly proton-pump inhibitors and the impact of these agents on real-world clinical effectiveness remains to be determined.

http://www.hepatitisc.uw.edu/page/treatment/drugs/epclusa

RECOMMENDED DOSAGE

The recommended dosage of Sofosvel/Velpanat is one tablet taken orally once daily with or without food [see Clinical Pharmacology (12.3)]. One tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. Table 1 shows the recommended treatment regimen and duration based on patient population.

Table 1 Recommended Treatment Regimen in Patients with Genotype 1, 2, 3, 4, 5, or 6 HCV
Patient Population Treatment Regimen and Duration
Patients without cirrhosis and patients with compensated cirrhosis (Child-Pugh A) Sofosvel/Velpanat 12 weeks
Patients with decompensated cirrhosis (Child-Pugh B or C) Sofosvel/Velpanat + ribavirin* 12 weeks
*
When administered with drug, the recommended dosage of ribavirin is based on weight (administered with food): 1000 mg per day for patients less than 75 kg and 1200 mg for those weighing at least 75 kg, divided and administered twice daily. The starting dosage and on-treatment dosage of ribavirin can be decreased based on hemoglobin and creatinine clearance. For ribavirin dosage modifications, refer to the ribavirin prescribing information.
NO DOSAGE RECOMMENDATIONS IN SEVERE RENAL IMPAIRMENT AND END STAGE RENAL DISEASE

No dosage recommendation can be given for patients with severe renal impairment (estimated Glomerular Filtration Rate [eGFR] less than 30 mL/min/1.73 m2) or with end stage renal disease (ESRD), due to higher exposures (up to 20-fold) of the predominant sofosbuvir metabolite [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

 

Common side effects (in more than 10% of people) are headache, fatigue and nausea.